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El Programa Alcohol de la Red de Trastornos Adictivos (RTA) requiere de un 
estudio clínico longitudinal para dar respuesta a preguntas de investigación en 
el trastorno por uso de alcohol. El proyecto CohRTA es un estudio multicéntrico 
de investigación cooperativa que se pone en marcha para mejorar la prevención 
secundaria y el diagnóstico precoz de los procesos patológicos asociados al 
trastorno por uso de alcohol.
Método: estudio observacional en cohorte multicéntrica de pacientes mayores 
de 18 años que solicitan tratamiento del trastorno por primera vez y autorizan 
su participación. La información clínica se recoge en una plataforma online 
diseñada para el estudio y puede ir acompañada de una muestra biológica 
que se deposita en un biobanco. Se recogen datos basales y prospectivos, 
sociodemográficos, epidemiológicos, clínicos y de tratamiento. A diciembre de 
2015 son 10 los centros proveedores de pacientes y se espera reclutar más de 
1.000 pacientes en los próximos años. 
Resultados: se dispone de 344 pacientes (77% hombres) que cumplen los 
criterios de inclusión en el estudio y con una edad de 50 años (RIQ: 43-55 años). 
La edad de inicio de consumo de alcohol fue de 15 años (RIQ: 14-18 años) y 
un 61% tenían antecedente familiar de trastorno por uso de alcohol. Durante 
los 30 días previos al inicio del tratamiento los pacientes bebían 12.5 UBE/
día (RIQ: 7.1-20 UBE/día), el 72% fumaba tabaco y el 30% consumía cocaína.
Conclusiones: Disponer de una cohorte abierta y multicéntrica de pacientes 
con trastorno por uso de alcohol será útil para analizar las consecuencias del 
abuso de alcohol, potenciar la investigación traslacional y añadir valor a la 
investigación clínica y básica del Programa Alcohol dentro de RTA/RETICS. 
Con una cohorte bien establecida y representativa se espera aumentar la 
cantidad y calidad científica en relación a las complicaciones del trastorno por 
uso de alcohol y sus consecuencias clínicas y sociales en España.
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The Alcohol Program of the Spanish Network on Addictive Disorders-RTA 
requires a longitudinal study to address different research questions related to 
alcoholism. The cohort study (CohRTA) focuses on patients seeking treatment 
for alcohol use disorder, as a multicentre, collaborative research project aimed 
to improve secondary prevention and early diagnosis of pathological processes 
associated with the disorder.
Methods: multicentre cohort study in adults (>18 years) seeking their first 
treatment of the disorder. Patients sign an informed consent and data is 
collected in an online platform specifically designed for the study; patients 
are also requested to provide biological samples that are stored in a biobank. 
Baseline and prospective, socio-demographic, epidemiological, clinical and 
treatment data are collected. Currently there are 10 participating centres that 
expect to recruit more than 1,000 patients. 
Results: As of December 2015, 344 patients (77% men) were included. Median 
age at admission was 50 years (IQR: 43-55 years). Median age at the start of 
alcohol consumption was 15 years (IQR: 14-18 years) and 61% of cases reported 
antecedents of alcohol use disorder in the family. During the 30 days prior to 
admission, alcohol consumption amounted to 12.5 SDU/day (IQR: 7.1-20 SDU/
day), 72% of the patients were tobacco smokers and 30% currently used cocaine.
Organising an open cohort of patients with alcohol use disorder may be crucial 
to better understand the clinical consequences of alcoholism in Spain. This 
cohort may potentiate quantitative and qualitative research within the Spanish 
Network on Addictive Disorders-RTA/RETICS. Having a well-established, 
representative cohort of patients will increase translational research on 
consequences of alcoholism in our country.
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The World Health Organization estimates that 76 million people worldwide abuse alcohol or are alcohol-dependent (World Health Organi-zation, 2010). In Spain, the prevalence of alco-
hol use is high, given that 79% of the general population 
between the ages of 15-64 years has consumed alcohol 
over the last year (84% of men, 73% of women) and 11% 
drink alcohol daily, according to a 2009-2010 home-based 
interview (Observatorio Español sobre Drogas, 2011). This 
same survey considers that 4.4% of the general popula-
tion are hazardous drinkers (alcohol ingestion of over 50 
grams/day for men and 30 grams/day for women). In the 
age group between 15-24 years, the prevalence of hazar-
dous alcohol use in women is 6% and in men is 5% (Ob-
servatorio Español sobre Drogas, 2011) .
Health-related problems associated with alcohol abuse 
are relatively common among the Spanish population and, 
as a result, in the public health system. Furthermore, each 
year close to 30,000 people seek treatment for the disorder 
and up to 61% of these have also used cocaine (Observato-
rio Español sobre Drogas, 2011). 
Alcohol use disorder is a chronic illness that may be ac-
companied by numerous alterations of the body. The harm 
alcohol causes to organs and tissues basically depends on 
the total amount of ethanol ingested over one’s lifetime 
and the usage pattern, though genetic, biological and en-
vironmental variables also intervene; among the main alte-
rations of the body resulting of alcoholism, now defined as 
alcohol use disorder per the DSM-5 (American Psychiatric 
Association, 2013), are worth highlighting: hepatitis, neu-
ropsychiatric disorders, cardiovascular disease, infectious 
diseases and cancer; furthermore, the risk of suffering an 
illness associated with alcohol abuse starts with relatively 
low levels of daily alcohol ingestion (30g/day) (Thomas et 
al., 2000). 
The prognosis of many physical disorders derived of 
alcohol abuse also depends on diverse factors. Alcohol 
may cause lesions to organs and systems after prolon-
ged consumption, but also in the short term, after binge 
drinking, or in the context of alcohol poisoning. Marked 
differences also exist by gender: women are at a greater 
risk of developing hepatitis than men, and in recent years 
the higher risk of breast cancer in frequent drinkers has 
also been emphasised (Bagnardi, Blangiardo, La Vecchia, 
& Corrao, 2001). On another hand, exaggerated alcohol 
use would also explain a significant part of mortality re-
sulting of non-intentional lesions (accidents, drowning, 
hypothermia, burns), intentional lesions (suicide) or 
other serious illnesses with high mortality during an acute 
episode (Naimi et al., 2003). In any case, the mortality of 
patients with alcohol use disorder is high, even up to 20 
times greater than that of the general population of the 
same age (Fuster et al., 2015; Rivas et al., 2013; Roerecke 
& Rehm, 2013). 
Another aspect to be considered in the current epide-
miology of alcohol use disorder is concurrence of the use 
of other substances, especially cocaine, cannabis and tobac-
co (Fuster et al., 2015; Observatorio Español sobre Drogas, 
2011; Rivas et al., 2013). The use of cocaine in combination 
with alcohol increases the plasma levels of cocaine by up 
to 30%, thereby entailing the risk of developing a cardio-
vascular disease, in addition to generating cocaethylene, 
a metabolic intermediary that is highly psychotropic and 
with cardiotoxic effects (Pennings, Leccese, & de Wolff, 
2002). From a behavioural perspective, the use of cocaine 
facilitates the use of alcohol in that the ingestion of co-
caine allows for drinking alcohol for a longer time period 
which, in turn, may increase the amount of cocaine used 
(Gossop, Manning, & Ridge, 2006). 
It is well known that clinical information contributed 
by case series are essential for improving the quality of at-
tention and for updating the prognosis of any illness. In 
this regard, having a cohort of patients with alcohol use 
disorder may be key for improving treatment of this illness 
and for promoting patient-focused research. In fact, revita-
lising clinical research is a main objective of Spanish and 
European research bodies; furthermore, the treatment of 
patients should be the bridge between basic science and cli-
nical effectiveness (Pons, Rodés, Andreu, & Arenas, 2013).
The Network on Addiction Disorders (RTA) is one of 
the Thematic Networks for Cooperative Research in Heal-
th (RETICS) of the Carlos III Health Institute. Since its 
founding in 2003, the scientific objectives of the RTA focus 
on substance abuse-related research and, since the phase 
launched in 2013, on the two substances of greatest socie-
tal impact: alcohol and cocaine.
The RTA Alcohol Program has driven the creation of a 
multicentre cohort study of patients seeking treatment for 
the disorder for the first time (CohRTA project). In cohort 
studies, patients are selected in accordance with a specific 
characteristic or exposure factors, and after the initial visit 
are monitored by the recruitment centre to analyse long-
term changes and the development of clinical impacts, de-
pending on the various exposure factors. This RTA study’s 
objectives and action plan have been presented in scienti-
fic congresses of the Spanish Society of Internal Medicine 
(SEMI) and the Spanish Scientific Society for Research on 
Alcohol, Alcoholism and Other Drug Addictions (Socidro-
galcohol). In addition to financial support provided by 
ISCIII, the CohRTA project received additional financial 
assistance from the 2014 research grants of the National 
Drug Plan (PNSD); additional support by the PNSD has 
allowed for extending the project to clinics beyond the 
RTA, increasing the number of cases, as well as the external 
validity, of the cohort study.
The ultimate aim of the study is to establish a stable pla-
tform of treatment centres to promote clinical and basic 
knowledge on alcohol use disorder. 
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Method
Study design
CohRTA is an open, prospective and multicentre cohort 
study of adults seeking treatment for alcohol use disorder 
for the first time. This study is linked to treatment centres 
of the National Public Health System belonging to the RE-
TICS Network of Addiction Disorders as well as others inte-
rested in participating after receiving a proposal. 
In its initial phases, the project had 10 participating cen-
tres and 1 biobank for collecting biological samples from 
cohort study patients. Table 1 displays the centres partici-
pating in the study and their characteristics.
Patient recruitment began in June 2013, upon official 
project approval by the Clinical Research Ethics Commi-
ttee (CEIC) of the centre coordinating the study, though 
each centre launched its recruitment as of the approval of 
its own CEIC (Table 1). Patients must meet the following 
criteria for inclusion in the multicentre cohort study: be 
over the age of 18, have a diagnosis of alcohol use disorder 
in accordance with the criteria of the DSM-5 (American 
Psychiatric Association, 2013) and sign an informed con-
sent form for disclosing personal data and submitting bio-
logical samples.
Ethical issues
Each participating centre coordinated with its own CEIC 
the approval of the study protocol and the informed con-
sent form to be given to the patients during their first visit. 
The informed consent form for the use of clinical data and 
biological samples was designed jointly with members of 
the RTA Biobank at the Miguel Hernández University in 
San Juan de Alicante, and was approved by each participa-
ting centre’s CEIC. 
Furthermore, the project is also recognised by the Spa-
nish Agency of Medicines and Medical Devices as a non 
post-authorization Observational Study (No-EPA).
Patients signing the informed consent form do so under 
the premise that the data provided is anonymous and that 
consent is revocable at any time, as per the Spanish Orga-
nic Law on Data Protection. The informed consent also 
offers patients the option of providing only clinical data.
Registered information
Two structured questionnaires were designed: one for 
use upon the patient’s inclusion in the cohort study and 
another for use during follow-up visits. 
The baseline questionnaire includes variables concer-
ning sociodemographic data, family history, alcohol use 
and substance abuse, and variables related to clinical symp-
toms, results of analyses and treatment of the disorder. 
The Cumulative Illness Rating Scale-Substance Abuse 
(CIRS-SA) index is used to evaluate clinical comorbidity 
of patients participating in the study (Castillo et al., 2004). 
This tool analyses the presence or absence of illness in 13 
organs or systems: 1) Cardio, 2) Vascular, 3) Respiratory, 
4) Eyes, ears, nose, throat and larynx, 5) Upper gastroin-
testinal, 6) Lower gastrointestinal, 7) Liver, 8) Renal, 9) 
Genital-urinary, 10) Muscular-skeletal, 11) Neurological, 
12) Infections, endocrinological, metabolical, and 13) HIV 
infection.
Table 1. Centres participating in the CohRTA study, Alcohol Program, Network on Addiction Disorders (RTA), up to December 2015.
Centre City Treatment type Profile Association CEIC Code
Hospital Univ. Germans  
Trias i Pujol* Badalona Addiction Unit Internal Medicine RETICS / PNSD PI-13-031
Hospital del Mar Barcelona Addiction Unit Psychiatry RETICS 2013/5313/I
Hospital Clínic de Barcelona Barcelona Alcoholism Unit Psychiatry RETICS 2013/8738
Hospital Universitari de Bellvitge L’Hospitalet de Llobregat Addiction Unit Internal Medicine PNSD PR049/14
Hospital Clínico Universitario Salamanca Department of Internal Medicine Internal Medicine RETICS E.O. 13/337
Hospital 12 de Octubre Madrid Psychiatry Department Psychiatry RETICS 15/065
Universidad de Valladolid Valladolid
Recovered Alcoholics  
of Valladolid (ARVA) Primary Care RETICS PI13-120
Hospital Universitari Son Espases Palma de Mallorca
Alcohol-related Problems Unit 
(UPRA) Internal Medicine PNSD IB 2357/14 PI
Hospital Lucus Augusti Lugo Department of Internal Medicine Internal Medicine PNSD 2015/010
Delta Centre Badalona
Municipal Drug Addiction 
Treatment Centre Primary Care PNSD PI-13-031
Miguel Hernández University San Juan de Alicante Biobank RETICS
Note. *Coordination centre.
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In addition, each organ or system is scored between 0 
and 4 depending on the severity of the impact: 0, no im-
pact; 1, mild impact (current mild problem or background 
of significant problem); 2, moderate impact (moderate 
disability or morbidity requiring first-line treatment); 3, 
severe impact (severe/continuous disability or uncontro-
llable chronic problems); 4, highly severe impact (extre-
mely serious/requires immediate treatment/organic insu-
fficiency/severe functional deterioration). 
To evaluate psychiatric comorbidity, the CohRTA study 
screens for depression, psychosis, attention deficit hype-
ractivity, posttraumatic stress, generalized anxiety, panic, 
social phobia and mania disorders.
Table 2 displays a detailed summary of these variables.
The patients’ follow-up questionnaire includes data on 
alcohol use after the first treatment, in addition to the de-
veloped of clinical symptoms and death.
Also, the option of adding a series of specific modules to 
the study’s initial protocol for further study has been fore-
seen; among these, some centres have already begun using 
the PRISM (Psychiatric Research Interview for Substance 
and Mental Disorder). Others are being considered, such 
as suicidal ideation, use of public health services and quali-
ty of life. For now, a model that includes the SF-12 general 
health survey has been used.
The SF-12 survey is comprised of 12 questions that offer 
a subjective assessment of health status. Eight aspects are 
evaluated: physical conditions, limitations caused by phy-
sical health problems, social functioning, bodily pain, 
mental health, limitations caused by personal or emotional 
problems, vitality and overall health. It is a brief version 
of the SF-36 survey, validated in different populations and 
countries, and sensitive to therapeutic changes (Gandek 
et al., 1998; Salyers, Bosworth, Swanson, Lamb-Pagone, & 
Osher, 2000).
Data collection process
Each participating centre has a designated person in 
charge of collecting data from patients in the study. Sto-
rage and periodical update of this information are perfor-
med using a platform designed for this purpose (Coresoft 
Clínico, www.coresoft.es) for professionals dedicated to 
the development, maintenance and support of online cli-
nical records, in compliance with the Organic Law on Data 
Protection, as well as current legislation on security and 
confidentiality. The use of this application for data entry 
was scheduled in two phases: an initial phase (September 
2014), when the information modules were available with 
regards to sociodemographic variables and drug use, acces-
sible only by RTA groups, and a second phase (September 
2015), when the clinical modules were implemented and 
access to the platform was open to all clinical groups inclu-
ded thanks to the additional financial assistance granted 
by the PNSD.
Table 2. Study variables of patients participating in the CohRTA 






Biological sample collection and date
Sociodemographics
Marital status
Socioeconomic and employment status
Level of education
Diagnosis Severity of alcohol use disorder as per DSM-5
Alcohol use
History of use




Use of other 
substances
Tobacco (history of use, current use pattern)
Cocaine (history of use, current use pattern)
Cannabis (current use pattern)
Amphetamines (current use pattern)
Hallucinogens (current use pattern)
Opioids (current use pattern)
Inhalants (current use pattern)
Emerging drugs (current use pattern)





Anaemia diagnosis (8 parameters)
Serology test to identify viruses (10 parameters)
Drugs in urine (opioids, cocaine, cannabis, 
amphetamines)
Comorbidity
Organic as per CIRS-SA**
Psychiatric as per screening for different 
pathologies
Treatment
Pharmacological (drugs, start/end dates, 
prescribed dose)
Non-pharmacological, therapeutic interventions 
(type and date)
Note. *Current use is defined as use over the last 30 days; **Cumulative Illness 
Rating Scale-Substance Abuse. 
Biobank
The centres participating in the CohRTA study have a 
biobank as reference for reception and storage of biologi-
cal samples. Each sample is linked with the clinical databa-
se by a patient code identification number. The biological 
sample collected is the extraction of 10 mL of blood for 
processing to obtain DNA. 
The CohRTA project’s biobank is located at the Neu-
roscience Institute of the Miguel Hernández University in 
San Juan de Alicante. The biobank has a scientific com-
mittee comprised of the RTA Coordinator, a local Mana-
ger and Researchers belonging to the network. The bio-
bank management system complies with the UNE-EN-ISO 
9001:2008 international standard (Registration Number 
ER-0614/2010).
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Current legislation permits ceding biological samples to 
research projects of the RTA on alcohol use disorder, upon 
prior authorization granted by an Ethics Committee. 
Authorship criteria
The CohRTA project has a document on criteria applica-
ble for scientific authorship of the project’s results. These 
criteria define an order for the authors in the heading of 
scientific articles and presentations made at congresses, and 
determine the content of the Annex reflecting the different 
participants and research centres. Different authorship cri-
teria are set forth, depending on the level of participation, 
use of samples and/or clinical data, and whether the pro-
jects have been implemented by members of the CohRTA 
project or by other preclinical researchers of the RTA who 
may use biological samples of CohRTA project patients.
Data analysis
Variables for sociodemographic data, use of alcohol 
and consumption of other drugs for all patients registered 
between June 2013 and November 2015 were extracted 
from the application. Descriptive analysis of the data was 
performed: continuous variables were described using the 
median and the interquartile range (IQR) and categorical 
variables were expressed as relative frequencies. The SPSS 
Statistics 15.0 package was used for data analysis (SPSS, 
Chicago, IL, USA). 
Results
Between June 2013 and November 2015, 344 patients; 
264 (76,7%) were men; median age at inclusion was 50 
(IQR: 43-55). Age at onset of alcohol use was 15 years 
(IQR: 14-18 years) and 61% had a family history of alcohol 
use disorder. During the 30 days preceding the start of the 
treatment, the patients ingested a median of 12.5 SDU/day 
(IQR: 7.1-20 SDU/day), 72% were tobacco smokers and 
29,7% used cocaine. Table 3 displays sociodemographic 
data and the history of use of alcohol and other substances. 
Of those patients included in the CohRTA project, there 
are currently 76 blood samples ready for a DNA analysis. 
The fact that this study is associated with a repository of 
biological samples will enable a series of projects in which 
preclinical groups with experience in animal-based models 
may transfer their hypotheses to research with humans.
Given the potential of clinical and biological data collec-
table through this study, it may serve as a platform for tra-
ining new clinical researchers in Spain and for publishing 
doctoral theses. The integration of different centres and 
the participation of clinical treatment groups in scientific 
settings may foster research by making available suitable 
methods for addressing the challenges of diagnosis, prog-
nosis and treatment of the illness. Furthermore, the public 
health system and RETICS scientific policy support these 
types of projects, patient-oriented and based on national 
research structures. ISCIII research training programs, like 
Rio Hortega and Juan Rodés, focus on improving the re-
search skills of young physicians.
In summary, with a consolidated cohort of patients, we 
expect to increase the volume and quality of scientific stu-
dies on complications arising of alcohol use disorder and 
its clinical and social consequences in Spain.
Discussion
The demand for treatment of alcohol use disorder in 
Spain has grown. The profile of patients seeking treatment 
for the disorder is: middle-aged adults, predominantly 
men, and who might use cocaine and cannabis. This profi-
le is similar to the description of patients with alcohol use 
disorder or hazardous alcohol use receiving brief inter-
ventions in emergency services, primary care and during 
hospitalization for other reasons (Heather, 2014; Mdege 
et al., 2013; Nilsen et al., 2008). This study’s results reveal 
the severity of the disorder in those seeking treatment for 
the first time, and confirm that this occurs, on the average, 
30 years after the onset of alcohol use. A recent, systematic 
review of the disorder shows that the first treatment episo-
de is late and occurs when the disorder is clinically establi-
shed (Connor, Haber & Hall, 2016). Moreover, two-thirds 
of the patients had a family history of alcohol use disorder; 
in fact, this is one of the previously mentioned risk factors 
for this illness (Connor et al., 2016).
Given the scarcity of multicentre studies in Spain on this 
pathology, the research project presented herein will allow 
for knowing the clinical dimension of the problem, its treat-
ment and, in summary, will update the illness’ prognosis. In 
addition, the study will generate knowledge on alcohol use by 
women and its long-term consequences, which to date have 
not been clearly defined; women with alcohol use disorder 
represent merely 20% of the total, and requires a broad re-
cruitment of cases to obtain a representative sample. Further-
more, the results obtained through this project may be useful 
for proposing new diagnosis strategies for the disorder. 
The capacity for research and transfer of knowledge is 
key for multicentre projects. Working as a network provides 
the opportunity for disseminating patient-oriented research. 
Bringing clinical and basic groups with similar interests to-
gether poses countless advantages and the CohRTA project 
may act as a suitable platform for adapting to future research. 
Cohort studies have entailed a radical change in our 
knowledge of certain illnesses. As just one example, a signi-
ficant part of current knowledge on the risk of developing 
cardiovascular diseases is due to the Framingham study 
(USA), a prospective cohort study that began its recruit-
ment in 1948 to establish today’s most well-known risk fac-
tors of cardiovascular disease (McKee, Castelli, McNama-
ra, & Kannel, 1971). Years later, the longitudinal research 
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model for this illness has been implemented in our society 
(Nascetti et al., 2001) as also occurred for others, such as 
HIV/AIDS (Sobrino-Vegas et al., 2011) and thromboem-
bolism (Nieto & Monreal, 2004); all of these have notably 
increased knowledge through an excellent scientific pro-
duction in their respective knowledge areas. 
Several cohort studies have been developed on alcohol 
use and drug addiction in our country. Worth mentio-
ning, for example, are a cohort of 850 patients who sought 
treatment for alcohol abuse at the end of the 1980s (Gual, 
Lligona, & Colom, 1999; Gual, Lligoña, Costa, Segura, & 
Colom, 2004), the Itinere cohort with patients who were 
heroin and cocaine users (Pulido et al., 2009) or the study 
with almost 6,000 patients hospitalised in Hospital De-
toxification Units in Barcelona and its metropolitan area, 
1,200 of these for alcohol dependency (Rivas et al., 2013; 
Sanvisens et al., 2014). 
The CohRTA project is specifically designed to analyse 
patients with alcohol use disorder seeking treatment for 
the disorder for the first time; the study is nested in first-li-
ne treatment centres, is rich in clinical and biological data, 
is patient-centred, and is focused on detecting the mid and 
long-term impact of alcoholism. However, these types of 
studies imply several limitations, the main one of which de-
rives of its longitudinal nature. Longitudinal studies are ex-
pensive, require special dedication for follow-up of all ca-
ses over a long period of time and qualified personnel for 
data updates and statistical analysis. Secondly, this study’s 
multicentre feature may incorporate an inter-observer bias 
for certain variables requiring interpretation (i.e., clinical 
and psychiatric comorbidity), though efforts are made to 
minimise this aspect through the publication of sufficiently 
detailed guides on data collection.
Nevertheless, the scientific level of the groups partici-
pating in CohRTA, whether in treatment for the disorder 
(Gual & Miquel, 2015; López-Pelayo et al., 2014), neuro-
inflammation and brain damage (Montesinos et al., 2015; 
Pascual, Baliño, Aragón, & Guerri, 2015), immunity and 
genetics associated with alcoholic hepatitis (Chamorro et 
al., 2014; Novo-Veleiro et al., 2014), comorbidity and mor-
tality (Rivas et al., 2013; Sanvisens et al., 2014) or the Public 
Health perspective of the problem (Bosque-Prous et al., 
2014; Villalbí, Bosque-Prous, Gili-Miner, Espelt, & Brugal, 
2014) guarantee the project’s viability.
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Appendix 
Network on Addiction Disorders (RTA), Alcohol Pro-
gram Coordination: Fernando Rodríguez de Fonseca, Ma-
laga Biomedical Research Institute, Malaga.
Table 3. Sociodemographic data, use of alcohol and consumption 
of other substances in 344 patients with alcohol use disorder 






Age, median [IQR] 50 [43-55]
Spanish 324 (94.2)
Marital status (n = 335)
   Unmarried
   Married – Cohabitation
   Widowed





Employment (n = 337)
  Employed
  Unemployed
  Permanent disability / pensioner





Use of alcohol and other drugs 
Severity of alcohol use disorder as per DSM-5 (n = 340)
   2-5
   6-8




Age at onset of alcohol use, median [IQR] 15 [14-18]
Age at onset of regular alcohol use, median [IQR] 22 [18-30]
SDU/day, last 30 days, median [IQR] 12,5 [7.1-20]
Period of total abstinence from alcohol (years),  
median [IQR] 1 [0-3]
Family history of alcohol use disorder (n = 334) 203 (60.8)
Number of alcohol poisonings requiring medical attention 
over the lifetime (n = 321)
   None
   1-5











Use in the last 30 days of:
   Cocaine
   Cannabis/marihuana
   Amphetamines
   Tranquillizers or benzodiazepines,  
without medical prescription






Antecedent of parenteral drug use 12 (3.5)
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